Avidity biosciences engages with patient communities during national muscular dystrophy awareness month as part of commitment to developing muscular dystrophy programs

Company remains on track to have three muscular dystrophy programs in clinic by end of year  san diego, sept. 7, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), honors national muscular dystrophy awareness month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.
RNA Ratings Summary
RNA Quant Ranking